DIADEM

Diadem is a diagnostic company focused on developing early peripheral markers of disease into advanced diagnostic technology. The company specializes in creating a blood-based test that targets a specific conformation of the p53 protein, which has shown high sensitivity and specificity for Alzheimer's Disease (AD) in pilot clinical studies. This test, known as Predict, can identify the risk of cognitive decline in both symptomatic and asymptomatic elderly patients, enabling early intervention and more effective drug development. Diadem's core market includes healthcare providers, pharmaceutical companies, and clinical research organizations. The business model revolves around providing diagnostic tests that are fast, cost-effective, and non-invasive, thereby generating revenue through test sales and partnerships with pharmaceutical companies for clinical trials. The company's innovative approach aims to improve patient outcomes and streamline the drug development process for AD.

Keywords: Alzheimer's, diagnostic, blood test, p53 protein, cognitive decline, early detection, non-invasive, predictive, healthcare, clinical trials.